Reata Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that announced abstracts of study which highlighted clinical data for bardoxolone methyl (“bardoxolone”). It will be presented at two upcoming nephrology conferences. The conferences are The World Congress of Nephrology 2021, being held virtually from April 15 – 19, 2021, and the 58th European Renal Association and European Dialysis and Transplant Association (“ERA-EDTA”) Congress being held from June 5 – 8, 2021, in Berlin, Germany will present the data.
Bardoxolone is an investigational, one tablet daily, orally administered activator of Nrf2. There is a transcription factor that induces the molecular pathways that promote the resolution of inflammation. It restores the mitochondrial function and reduces oxidative stress. The US FDA has granted Orphan Drug designated to the bardoxolone to treat Alport syndrome and autosomal dominant polycystic kidney disease (“ADPKD”).
The CARDINAL Phase 3 study, bardoxolone, is under investigation in FALCON. It is a phase 3 study for treating ADPKD, MERLIN, a Phase 2 study to treat patients with CKD at risk of rapid progression. In the PHOENIX Phase 2 study, bardoxolone treatment produced positive results in patients with CDK caused by ADPKD.
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients suffering from severe or life-threatening diseases. Bardoxolone and omaveloxolone are two of the most advanced clinical candidates.
Be First to Comment